X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TTK HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA TTK HEALTHCARE CIPLA/
TTK HEALTHCARE
 
P/E (TTM) x 39.8 22.0 180.7% View Chart
P/BV x 3.7 7.4 49.4% View Chart
Dividend Yield % 0.5 0.4 118.1%  

Financials

 CIPLA   TTK HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-18
TTK HEALTHCARE
Mar-14
CIPLA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs663663 99.9%   
Low Rs479399 120.1%   
Sales per share (Unadj.) Rs189.0535.6 35.3%  
Earnings per share (Unadj.) Rs17.615.9 110.3%  
Cash flow per share (Unadj.) Rs34.020.0 169.9%  
Dividends per share (Unadj.) Rs3.004.00 75.0%  
Dividend yield (eoy) %0.50.8 69.8%  
Book value per share (Unadj.) Rs176.7137.6 128.4%  
Shares outstanding (eoy) m805.127.77 10,361.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.0 304.6%   
Avg P/E ratio x32.533.3 97.4%  
P/CF ratio (eoy) x16.826.5 63.3%  
Price / Book Value ratio x3.23.9 83.7%  
Dividend payout %17.125.1 68.0%   
Avg Mkt Cap Rs m459,7244,127 11,138.3%   
No. of employees `00023.61.7 1,382.3%   
Total wages/salary Rs m26,901607 4,434.7%   
Avg. sales/employee Rs Th6,446.12,436.7 264.5%   
Avg. wages/employee Rs Th1,139.4355.2 320.8%   
Avg. net profit/employee Rs Th600.072.5 827.1%   
INCOME DATA
Net Sales Rs m152,1934,162 3,656.9%  
Other income Rs m3,57761 5,844.0%   
Total revenues Rs m155,7694,223 3,688.6%   
Gross profit Rs m28,264197 14,339.8%  
Depreciation Rs m13,22832 41,729.3%   
Interest Rs m1,14230 3,820.4%   
Profit before tax Rs m17,470197 8,881.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,50173 3,435.6%   
Profit after tax Rs m14,166124 11,433.2%  
Gross profit margin %18.64.7 392.1%  
Effective tax rate %14.337.0 38.7%   
Net profit margin %9.33.0 312.6%  
BALANCE SHEET DATA
Current assets Rs m108,1411,629 6,639.7%   
Current liabilities Rs m38,3221,058 3,622.8%   
Net working cap to sales %45.913.7 334.4%  
Current ratio x2.81.5 183.3%  
Inventory Days Days9730 325.8%  
Debtors Days Days7434 221.5%  
Net fixed assets Rs m109,411556 19,667.7%   
Share capital Rs m1,61078 2,072.3%   
"Free" reserves Rs m140,682878 16,017.5%   
Net worth Rs m142,2921,069 13,307.0%   
Long term debt Rs m36,621159 23,075.7%   
Total assets Rs m228,6062,399 9,527.6%  
Interest coverage x16.37.6 215.0%   
Debt to equity ratio x0.30.1 173.4%  
Sales to assets ratio x0.71.7 38.4%   
Return on assets %6.76.4 104.5%  
Return on equity %10.011.6 85.9%  
Return on capital %10.018.5 53.9%  
Exports to sales %32.80.8 4,146.1%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs m49,88333 151,619.1%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m51,69133 157,115.2%   
Fx outflow Rs m21,03363 33,285.8%   
Net fx Rs m30,658-30 -101,213.6%   
CASH FLOW
From Operations Rs m14,628127 11,554.2%  
From Investments Rs m-8,540-146 5,849.4%  
From Financial Activity Rs m-3,85522 -17,601.8%  
Net Cashflow Rs m2,4313 97,244.0%  

Share Holding

Indian Promoters % 16.0 65.4 24.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 3.7 329.7%  
FIIs % 23.7 5.2 455.8%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.8 101.6%  
Shareholders   161,166 12,723 1,266.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PFIZER  NATCO PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 17, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS